Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 25,196

Document Document Title
WO/2022/115879A1
The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.  
WO/2022/111202A1
Disclosed in the present invention are a 3,5-dimethyl-4-sulfone group-1H-pyrrole compound, a preparation method therefor, and a use thereof. The chemical structure is shown in formula I. R1 and R2 are H, methyl, ethyl or isopropyl; R3 is...  
WO/2022/104636A1
An autophagy targeting chimera and an application thereof, and a targeted protein degradation method using an autophagic degradation targeting protein. In the method, the autophagy targeting chimera is used to mediate autophagic degradat...  
WO/2022/107724A1
The present invention provides: a novel azetidinone derivative having excellent herbicidal activity, or a salt thereof; an herbicide containing the same as an active ingredient; and a production intermediate. Provided are: an azetidinone...  
WO/2022/105986A1
The present invention relates to novel physiological cooling agents, cooling agent mixtures containing said novel substances, mixtures of cooling agents with flavours, the use of said cooling agents and objects and final preparations for...  
WO/2022/106452A2
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...  
WO/2022/108068A1
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.  
WO/2022/105845A1
A glucoside derivative, and a preparation method therefor and an application thereof. Specifically, provided is a glucoside derivative, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The ...  
WO/2022/108141A1
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.  
WO/2022/101352A1
The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.  
WO/2022/103031A1
Provided is a triazine or pyrimidine derivative that contributes to a substantial improvement in lifespan of an organic electroluminescent element by effectively absorbing high energy in the UV range from an external light source to mini...  
WO/2022/102992A1
The present invention provides a novel compound and an organic light-emitting device using same.  
WO/2022/100624A1
A new compound effectively antagonizing LPAR. The new compound is a compound represented by the following formula, or is a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt, or a prodrug of the compound represented b...  
WO/2022/100623A1
Disclosed is a new class of compounds that effectively antagonize LPAR, which are compounds represented by the following formula, or a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compounds r...  
WO/2022/099011A1
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is...  
WO/2022/094354A1
The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of prep...  
WO/2022/092141A1
The present invention provides: a compound, or a pharmaceutically acceptable salt thereof, having an antiviral activity and represented by formula (I); and a pharmaceutical composition containing the same. (In the formula, the broken lin...  
WO/2022/092625A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a composition for an organic layer of an organic light-emitting device, and a method for ma...  
WO/2022/092638A1
Provided is a pyrimidin derivative substantially contributing to the driving voltage, efficiency and extended life of an organic electroluminescent device. The organic electroluminescent device according to the present invention comprise...  
WO/2022/088865A1
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element, and an electronic apparatus. The nitrogen-containing compound has a structure as represented...  
WO/2022/092180A1
To solve a food crisis associated with an increase in world population expected in the near future, the creation of novel herbicides having high safety for crops and excellent herbicidal activity against weeds is desired. The problem is ...  
WO/2022/089428A1
The present application relates to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element and an electronic device. The structure of the nitrogen-containing compound is as shown in fo...  
WO/2022/082817A1
The present invention relates to a 3-three-membered spirooxindole derivative synthesizing method, comprising: in a protective atmosphere and an organic solvent, using a 3-indoleethanol compound as a reaction raw material, and carrying ou...  
WO/2022/083598A1
The present application relates to the technical field of organic materials, and specifically disclosed therein are a nitrogen-containing compound and an electronic element and electronic apparatus using same, the nitrogen-containing com...  
WO/2022/084168A1
The present invention relates to 4,6-difluorodibenzothiophene derivatives of formulae I-1 and I-2, to a process for the preparation thereof, to liquid-crystalline (LC) media comprising these derivatives and to electro-optical devices and...  
WO/2022/084280A1
Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof wherein R1 and R2 represent a hydrogen atom or a deuterium atom; R3 represents a hydrogen atom, a -COOH group or a -OH group; R3' and R3" rep...  
WO/2022/080651A1
The present specification relates to: a heterocyclic compound of chemical formula 1; and an organic light-emitting device and an organic material layer forming composition, which comprise same.  
WO/2022/078428A1
Provided are a compound as a prolyl hydroxylase inhibitor and a preparation method therefor, which belong to the technical field of medicines. The compound is shown in formula I, has a prolyl hydroxylase inhibitory activity, and can be u...  
WO/2022/078306A1
The present invention relates to the technical field of organic synthesis and chemical catalysis. Disclosed are a large steric hinderance palladium-nitrogen-heterocyclic carbene complex, a preparation method for same, applications of sam...  
WO/2022/080927A1
The present invention relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.  
WO/2022/081807A1
The present invention provides acyl sulfonamide compounds of general formula (I): in which R1, R2, R3, R4, R5, R6ยท Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for pre...  
WO/2022/075566A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.  
WO/2022/076764A1
The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...  
WO/2022/076496A1
Invented are compounds of formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula (I), pharmaceutical compositions comprisi...  
WO/2022/075601A1
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.  
WO/2022/073904A1
This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.  
WO/2022/076495A1
Invented are compounds of Formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising c...  
WO/2022/076627A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases,...  
WO/2022/075787A1
The present invention relates to a pharmaceutical composition for preventing or treating diseases related to mitochondrial dysfunction, comprising a novel quinone derivative as an active ingredient, and provides a composition for prevent...  
WO/2022/074214A1
A process for the preparation of compound of formula I is provided: Formula (I) where R1 and R2 are as defined in the description.  
WO/2022/071484A1
The present invention relates to 3-hydroxyoxindole derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also...  
WO/2022/072975A1
In one aspect, the disclosure relates to viral papain protease inhibitors, methods of making the same, pharmaceutical compositions comprising the same, and methods of treating and/or preventing COVID-19 and other coronavirus diseases usi...  
WO/2022/068772A1
A compound related to formula (I), a preparation method therefor, and the use thereof in medicine. Specifically, provided are a compound related to formula (I) or a stereoisomer, a tautomer and a pharmaceutically acceptable salt thereof....  
WO/2022/067724A1
Provided are an SGLT-2 inhibitor sarcosine co-crystal, a preparation method therefor and use thereof. Using sarcosine as a ligand, said co-crystal has higher safety and lower costs; a drug co-crystal has higher stability, and during the ...  
WO/2022/065762A1
The present specification relates to: an organic light-emitting device comprising a first electrode, a second electrode, and one or more organic layers provided between the first electrode and the second electrode, wherein at least one o...  
WO/2022/065761A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic material layer.  
WO/2022/065730A1
Provided is a cyano group-substituted aryl or heteroaryl derivative which effectively absorbs high-energy light in the UV region from an external light source to minimize damage to organic materials inside an organic electroluminescent d...  
WO/2022/063317A1
Disclosed are a fused tricyclic derivative and a pharmaceutical application thereof. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.  
WO/2022/061193A1
Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in ...  
WO/2022/058327A1
The present invention relates to compound of formula (I): wherein the variables are defined as in claim 1, to compositions comprising at least one of said compounds and at least one agriculturally suitable auxiliary, to the use of said c...  

Matches 701 - 750 out of 25,196